Croda International completes acquisition of Avanti Polar Lipids

Laboratory Spiritus Mundi

Croda International Plc (LON:CRDA) has confirmed that, following approval from the US regulatory authorities, it has now successfully completed the acquisition of Avanti Polar Lipids, Inc., a leader in drug delivery systems for next generation pharmaceuticals. 

For further information see the announcement of the acquisition signing dated 6 July 2020. 

Croda International is the speciality chemical company that creates high performance ingredients and technologies relied upon by industries and consumers globally. More at www.croda.com.

Share on:

Latest Company News

Croda reports 6.6% sales growth in Q3 2026 as beauty and pharma demand improves

Croda International plc reports third-quarter sales growth of 6.6% on an organic basis to £449.9m, supported by strong demand...

Croda International reports 4.6% organic sales growth in first half of 2026

Croda International reported higher half-year sales, adjusted operating profit and free cash flow, while leaving its full-year 2026 outlook...

Croda posts stable Q1 2026 trading as Consumer Care offsets Life Sciences weakness

First-quarter sales were £431m, up 1% at constant currency against a strong prior-year comparator. Consumer Care growth, led by...

Croda International delivers 2025 earnings growth and targets higher margins by 2028

Croda reported 4.4% sales growth to £1.7bn in 2025, with adjusted operating profit up 7.9% at constant currency....

Croda International reports 6.5% sales growth in third quarter, outlook unchanged

Croda International reported third-quarter 2025 sales of £425 million, up 6.5% at constant currency, driven by strong performances in...

Croda H1 2025 sales Up 7% with adjusted profit before tax up 8%

Croda International delivered group sales of £855.8 m in the half year to 30 June 2025, up 7% at...

    Search